Literature DB >> 23943824

One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.

Sakib Burza1, Emara Nabi, Raman Mahajan, Gaurab Mitra, María Angeles Lima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23943824     DOI： 10.1093/cid/cit508

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

Review 1.  Recent developments and future prospects in the treatment of visceral leishmaniasis.

Authors:  Shyam Sundar; Anup Singh
Journal:  Ther Adv Infect Dis       Date:  2016-04-22

Review 2.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

Review 3.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

4.  Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.

Authors:  Sakib Burza; Prabhat K Sinha; Raman Mahajan; María Angeles Lima; Gaurab Mitra; Neena Verma; Manica Balasegaram; Manica Balasegarem; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

5.  Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.

Authors:  Sakib Burza; Prabhat K Sinha; Raman Mahajan; María Angeles Lima; Gaurab Mitra; Neena Verma; Manica Balasegaram; Manica Balsegaram; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

Review 6.  Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance.

Authors:  Marie-Claude N Laffitte; Philippe Leprohon; Barbara Papadopoulou; Marc Ouellette
Journal:  F1000Res       Date:  2016-09-20

7.  Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs.

Authors:  Alec O'Keeffe; Christine Hale; James A Cotton; Vanessa Yardley; Kapish Gupta; Abhishek Ananthanarayanan; Sudaxshina Murdan; Simon L Croft
Journal:  Microorganisms       Date:  2020-06-01

8.  Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.

Authors:  Tegwen Marlais; Tapan Bhattacharyya; Om Prakash Singh; Pascal Mertens; Quentin Gilleman; Caroline Thunissen; Bruno C Bremer Hinckel; Callum Pearson; Bathsheba L Gardner; Stephanie Airs; Marianne de la Roche; Kiera Hayes; Hannah Hafezi; Andrew K Falconar; Osama Eisa; Alfarazdeg Saad; Basudha Khanal; Narayan Raj Bhattarai; Suman Rijal; Marleen Boelaert; Sayda El-Safi; Shyam Sundar; Michael A Miles
Journal:  Front Cell Infect Microbiol       Date:  2018-12-13       Impact factor: 5.293

9.  Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).

Authors:  Sakib Burza; Raman Mahajan; Prabhat K Sinha; Johan van Griensven; Krishna Pandey; María Angeles Lima; Marta Gonzalez Sanz; Temmy Sunyoto; Sunil Kumar; Gaurab Mitra; Ranjeet Kumar; Neena Verma; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07

Review 10.  Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review.

Authors:  Siddhivinayak Hirve; Marleen Boelaert; Greg Matlashewski; Dinesh Mondal; Byron Arana; Axel Kroeger; Piero Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2016-08-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.